½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1444913

¼¼°è ÆóÈ°·®°è ½ÃÀå : Á¡À¯À² ºÐ¼®, ¾÷°è µ¿Çâ°ú Åë°è, ¼ºÀå ¿¹Ãø(2024-2029³â)

Spirometers - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Mordor Intelligence | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

ÆóÈ°·®°è ½ÃÀå ±Ô¸ð´Â 2024³â 6¾ï 270¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2029³â±îÁö 8¾ï 389¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç CAGR·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

ÆóÈ°·®°è - ½ÃÀå

COVID-19´Â È£Èí±â ÁúȯÀ¸·Î °íÅë¹Þ´Â ȯÀÚÀÇ Áø´Ü°ú Ä¡·áÀÇ °¨¼Ò·Î ½ºÆÄÀ̷ιÌÅÍ ½ÃÀåÀÇ ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÃƽÀ´Ï´Ù. ¿¹¸¦ µé¾î, 2021³â 9¿ù¿¡ Elsevier Public Health Emergency¿¡ °ÔÀçµÈ Á¶»ç ¿¬±¸¿¡ µû¸£¸é, ÆóÈ°·®ÃøÁ¤ÀÇ »ç¿ëÀº °ñ¼öÀ̽Ä, ÆóÀ̽Ä, È­Çпä¹ý Àü µî ±ä±Þ Ä¡·á¸¦ ¸ñÀûÀ¸·Î ÇÑ ¸é¿ª °áÇÌ È¯ÀÚ¿¡ ÇÑÁ¤µÇ¾î ÀÖ´Ù´Â °ÍÀÌ °üÂûµÇ¾ú½À´Ï´Ù. Ä¡·á¹ý. ¶ÇÇÑ 2021³â 2¿ù PLOS One¿¡ °ÔÀçµÈ Á¶»ç °á°ú¿¡ µû¸£¸é COPD ȯÀÚÀÇ Àü»çÀÎ »ç¸ÁÀ§ÇèÀº ºñ COPDȯÀÚ¿¡ ºñÇØ ¾à 2¹è ³ô¾Æ º´¿ø ÁøÂûÀÌ ±Þ°ÝÈ÷ °¨¼ÒÇÏ°í ÀÖÀ½ °üÂûµÇ¾ú½À´Ï´Ù. Á¤ºÎÀÇ ¶ô´Ù¿î Á¶Ä¡¿¡ ÀÇÇÑ Å¬¸®´Ð°ú Ŭ¸®´ÐÀº À¯Çà Áß ½ÃÀåÀÇ ¼ºÀå¿¡ ½É°¢ÇÑ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ±×·¯³ª È£Èí±â Áúȯ Áø´Ü ¹× Ä¡·á ¼­ºñ½º Àç°³ ¹× ȯÀÚ ¹æ¹® Áõ°¡·Î ½ÃÀå ¼ºÀåÀÌ Áõ°¡ÇÏ°í ¼ö³â¿¡ °ÉÃÄ ÀáÀç·ÂÀ» ȸº¹ÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç ¿¹Ãø ±â°£ µ¿¾È °ÇÀüÇÑ ¼ºÀåÀ» ±â·ÏÇÒ ¼ö ÀÖÀ½ ¼ºÀÌ ÀÖ½À´Ï´Ù.

¸¸¼º Æó»ö¼º ÆóÁúȯ(COPD)ÀÇ À¯º´·ü »ó½Â, ÆóÈ°·®°è ºÐ¾ßÀÇ ±â¼ú Áøº¸, ÀçÅà ÇコÄɾ ´ëÇÑ °ü½É Áõ°¡ µîÀÇ ¿äÀÎÀÌ ½ÃÀåÀÇ ¼ºÀåÀ» ¹Ð¾î ¿Ã¸®°í ÀÖ½À´Ï´Ù.

±¹¹Îµé »çÀÌ¿¡¼­ COPDÀÇ ºÎ´ãÀÌ Áõ°¡ÇÏ°í Àֱ⠶§¹®¿¡ COPD »óÅÂÀÇ Á¶±â ¹ß°ßÀÇ Çʿ伺ÀÌ ³ô¾ÆÁö°í ÀÖ¾î ÆóÈ°·® ÃøÁ¤ °Ë»ç ¼ö¿ä°¡ ³ô¾ÆÁú °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀÌ È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î 2021³â 11¿ù À¯·´È£Èí±â Àú³Î¿¡ °ÔÀçµÈ ±â»ç¿¡ µû¸£¸é 2020³â¿¡´Â 3,658¸¸ 965¸íÀ̾úÁö¸¸, 2050³â±îÁö ¾à 4,945¸¸ 3,852¸íÀÇ À¯·´ÀÎÀÌ COPD¿¡ ½Ã´Þ¸®¸é ¿¹»óµË´Ï´Ù. ¶ÇÇÑ °°Àº Ãâó¿¡ µû¸£¸é ³×´ú¶õµå´Â ´ÙÀ½°ú °°ÀÌ ¿¹»óµË´Ï´Ù. 2050³â±îÁö À¯·´¿¡¼­ COPDÀÇ À¯º´·üÀÌ °¡Àå ³ô¾ÆÁú °ÍÀ¸·Î ¿¹»óµË´Ï´Ù(14.6%).

°Ô´Ù°¡ 2021³â 1¿ù PLOS ONE¿¡ °ÔÀçµÈ ¿¬±¸¿¡ µû¸£¸é ÇÁ¶û½º¿¡¼­´Â ÇöÀç ¸¸¼ºÆó¼â¼º ÆóÁúȯ(COPD) ȯÀÚ°¡ 260¸¸¸í ÀÖ¾î 2025³â±îÁö ±× ¼ö´Â 280¸¸¸íÀ¸·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¶ÇÇÑ NHS°¡ ¹ßÇ¥ÇÑ 2022³â Åë°è¿¡ µû¸£¸é ¿µ±¹¿¡¼­´Â 2020³âºÎÅÍ 2021³â ¸¸¼ºÆó¼â¼º ÆóÁúȯ(COPD)À¸·Î Áø´Ü¹ÞÀº »ç¶÷Àº ¾à 117¸¸¸íÀ¸·Î ÃÑ Àα¸ÀÇ 1.9%¸¦ Â÷Áö . µû¶ó¼­ COPD·Î °íÅë¹Þ´Â »ç¶÷µéÀÇ ¼ö°¡ ¿¹»óµÇ´Â Áõ°¡·Î ÀÎÇØ ±â¼úÀûÀ¸·Î ÷´Ü ÆóÈ°·®°è¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ°í ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

°Ô´Ù°¡ ±â¼úÀÇ Áøº¸, ÀåÄ¡ÀÇ È޴뼺°ú Á¶ÀÛÀÇ ¿ëÀ̼ºÀÇ Çâ»ó¿¡ ÀÇÇØ ºÎ¹®ÀÇ ¼ºÀåÀÌ ÃËÁøµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î ºñ¾î¸® ¸ÞµðÄÃÀº 2021³â 3¿ù¿¡ È£ÁÖ ¹× ±âŸ ±¹°¡¸¦ Æ÷ÇÔÇÑ 15°³±¹ À̻󿡼­ AioCare(HealthUp SA, Æú¶õµå) ¸ð¹ÙÀÏ ÆóÈ°·® ÃøÁ¤ ½Ã½ºÅÛÀ» Ãâ½ÃÇß½À´Ï´Ù. ÀÌ ÀÓ»óÀûÀ¸·Î ÀÔÁõµÈ ±â¼úÀº ºñ¾ÆÀ̾îÀÇ ±íÀº È£Èí±â Áø´Ü Àü¹® Áö½ÄÀ» È®ÀåÇÏ¿© Àǻ簡 º´¿ø µî±Þ ÆóÈ°·®°è¸¸Å­ õ½Ä°ú COPD¸¦ Æ÷ÇÔÇÑ Æó ÁúȯÀ» ½Å¼ÓÇÏ°Ô Áø´ÜÇÒ ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù.

¶ÇÇÑ È¯ÀÚµé »çÀÌ¿¡¼­ ÀçÅà °Ç°­ °ü¸®¿¡ ´ëÇÑ ÁöÇ⼺ÀÌ ³ô¾ÆÁö¸é¼­ ¿ø°ÝÆóÈ°·®°è¿Í °¡»óÆóÈ°·®ÃøÁ¤°Ë»çÀÇ °³¹ßÀÌ Áõ°¡ÇÏ°í ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÏ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2021³â 6¿ù eResearch Technology(ERT)´Â ÀçÅà Æó ±â´É °Ë»ç(PFT) Áß¿¡ ½Ç½Ã°£ ÄÚĪÀ» Çã¿ëÇÏ´Â ERT iSpiro Virtual Visits¸¦ ½ÃÀÛÇß½À´Ï´Ù. iSpiro Virtual Visits¸¦ »ç¿ëÇϸé Áý¿¡¼­ °íÇ°ÁúÀÇ ÆóÈ°·® ÃøÁ¤ µ¥ÀÌÅ͸¦ ¼öÁýÇÒ ¼ö ÀÖÀ¸¹Ç·Î ȯÀÚ°¡ Ŭ¸®´ÐÀ» ¹æ¹®ÇÒ ¼ö ¾ø´Â °æ¿ì¿¡µµ È£Èí±â ÀÓ»ó ¿¬±¸¸¦ ÀÏÁ¤´ë·Î ÁøÇàÇÒ ¼ö ÀÖ½À´Ï´Ù.

µû¶ó¼­ ¾Õ¼­ ¾ð±ÞÇÑ ¿äÀεé·Î ÀÎÇØ Á¶»ç ´ë»ó ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±×·¯³ª ¸¸¼º Æó»ö¼º ÆóÁúȯ(COPD)¿¡ ´ëÇØ ¾Æ´Â »ç¶÷Àº ÃæºÐÇÏÁö ¾ÊÀ¸¸ç ¾ÕÀ¸·Î ¼ö³â°£ ÆóÈ°·®°è ½ÃÀåÀÇ ¼ºÀåÀÌ µÐÈ­µÉ ¼ö ÀÖ½À´Ï´Ù.

ÆóÈ°·®°è ½ÃÀå µ¿Çâ

ÇÚµåÇïµå´Â ÆóÈ°·®°è ½ÃÀå¿¡¼­ ´ëÆøÀûÀÎ ¼ºÀåÀÌ ¿¹»óµÈ´Ù.

ÇÚµåÇïµå ÆóÈ°·®°è ºÎ¹®Àº COPD ¹× õ½Ä Áõ·Ê ¼ö Áõ°¡, ¼¼°è Èí¿¬ÀÚ ¼ö Áõ°¡, ½ÅÁ¦Ç° Áõ°¡ µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È ÆóÈ°·®°è ½ÃÀåÀÌ Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÈÞ´ë¿ë ÆóÈ°·®°è´Â ÀÛ°í °¡º±°í ÈÞ´ë°¡ ¿ëÀÌÇϱ⠶§¹®¿¡ ¾÷°è¿¡¼­ Á¡Á¡ ´ëÁßÈ­µÇ°í ÀÖ½À´Ï´Ù. ÇÚµåÇïµå ÆóÈ°·®°è´Â »ç¿ëÇϱ⠽±°í º´¿ø ¹Û¿¡¼­µµ »ç¿ëÇÒ ¼ö ÀÖ´Â µî ±âÁ¸ÀÇ ÆóÈ°·®°è¿¡ ºñÇØ ÀÌÁ¡ÀÌ ÀÖ¾î ºÎ¹®ÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

2022³â 4¿ù¿¡ Primary Care Respiratory Medicine¿¡ °ÔÀçµÈ ±â»ç¿¡ µû¸£¸é, PIKO-6, COPD-6, PEF¶ó´Â 3°³ÀÇ ÈÞ´ë¿ë ÆóÈ°·®°èÀÇ Á¤¹Ðµµ°¡ ÃøÁ¤µÇ¾ú½À´Ï´Ù. PIKO-6ÀÇ Á¤È®µµ´Â COPD-6(0.91) ¹× PEF(0.82)º¸´Ù ³ôÀº(0.95) °ÍÀ¸·Î °üÂûµÇ¾ú½À´Ï´Ù. ¶ÇÇÑ µ¿ÀÏÇÑ Ãâó¿¡ µû¸£¸é PIKO-6 ¹× COPD-6°ú °°Àº ÈÞ´ë¿ë ÆóÈ°·®°è´Â COPD ȯÀÚÀÇ Áø´Ü°ú Áõ»óÀÇ ÁßÁõµµ¸¦ °áÁ¤ÇÏ´Â µ¥ µµ¿òÀÌ µÇ´Â ´Ù¾çÇÑ È£Èí±â´É ÁöÇ¥¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù. È¿°úÀûÀÎ Ä¡·á Àü·«ÀÇ ¼±ÅÃÀ» µ½½À´Ï´Ù. µû¶ó¼­ ÈÞ´ë¿ë ÆóÈ°·®°è´Â Á¤È®ÇÏ°í »ç¿ëÇϱ⠽±°í ȯÀÚ Ä£È­ÀûÀÌ°í Àú·ÅÇÑ ÈÞ´ë°¡ ½±±â ¶§¹®¿¡ 1 Â÷ Áø·á »ç¿ë¿¡ ÀÌ»óÀûÀ̸ç COPDÀÇ Á¶±â ¹ß°ßÀ»À§ÇÑ ½Ç¿ëÀûÀÎ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ°ÍÀº ȯÀÚµé »çÀÌÀÇ Ã¤¿ëÀ» Áõ°¡½ÃÅ°°í ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¶ÇÇÑ ±â¾÷ È°µ¿ÀÇ È°¼ºÈ­¿Í Á¦Ç° Ãâ½Ã Áõ°¡·Î ÈÞ´ë¿ë ÆóÈ°·®°è ÀåÄ¡ÀÇ °¡¿ë¼ºµµ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2021³â 11¿ù, Cipla´Â Àεµ¿¡¼­ ´º¸ðÅà ±â¹Ý ÈÞ´ë¿ë ¹«¼± ÆóÈ°·®°è¸¦ Ãâ½ÃÇß½À´Ï´Ù. ÀÌ È¸»ç´Â Àεµ¿¡¼­ ÆóÀÇ ¸®´õ·Î¼­ÀÇ ÁöÀ§¸¦ °­È­ÇÏ·Á´Â ¾ß¸Á¿¡ µû¶ó ÀÌ ¹ßÇ¥¿¡ ÀÇÇØ Æó»ö¼º±âµµÁúȯ(OAD) Áø´Ü¿¡ Çõ¸íÀ» ÀÏÀ¸Å³ °ÍÀÔ´Ï´Ù.

µû¶ó¼­ Èí¿¬ÀÚ ¼ö Áõ°¡, COPD ºÎ´ã Áõ°¡, Á¦Ç° Ãâ½Ã Áõ°¡ µî ¾Õ¼­ ¾ð±ÞÇÑ ¿äÀÎÀ¸·Î ÀÎÇØ Á¶»ç ´ë»ó ºÎ¹®ÀÌ ¿¹Ãø ±â°£ µ¿¾È ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºÏ¹Ì´Â ¿¹Ãø ±â°£ µ¿¾È »ó´çÇÑ ½ÃÀå Á¡À¯À²À» °¡Áú °ÍÀ¸·Î ¿¹»ó

ºÏ¹Ì¿¡¼­´Â ¿¹Ãø ±â°£ µ¿¾È ÆóÈ°·®°è ½ÃÀåÀÌ °ÇÀüÇÏ°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÏ´Â ¿äÀÎÀ¸·Î´Â È£Èí±â ÁúȯÀÇ À¯º´·ü°ú ¹ß»ý·ü »ó½Â, È®¸³µÈ ÇコÄɾî ÀÎÇÁ¶óÀÇ Á¸Àç¿Í °í¾×ÀÇ ÇコÄɾî ÁöÃâ, ¼ÒºñÀÚ »çÀÌ¿¡¼­ÀÇ °¡Á¤¿ë °Ç°­±â±âÀÇ º¸±Þ ¸¦ µé ¼ö ÀÖ½À´Ï´Ù.

õ½Ä, COPD µî È£Èí±â Áúȯ ºÎ´ã Áõ°¡·Î ÆóÈ°·®°è ¼ö¿ä°¡ Áõ°¡ÇÏ¿© ½ÃÀå ¼ºÀåÀÌ ÃËÁøµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, ¹Ì±¹ õ½Ä ¾Ë·¹¸£±â Àç´Ü(AAFA)¿¡ µû¸£¸é 2022³â 4¿ù ÇöÀç ¹Ì±¹ÀÎÀÇ ¾à 13¸í Áß 1¸í, Áï ¾à 2,500¸¸ ¸íÀÌ Ãµ½ÄÀ» ¾Î°í ÀÖ¾ú½À´Ï´Ù. °°Àº Ãâó¿¡ µû¸£¸é ¾à 510¸¸ ¸íÀÇ ¹Ì±¹ ¾î¸°ÀÌ°¡ 18¼¼ ¹Ì¸¸ÀÇ Ãµ½ÄÀ» ¾Î°í ÀÖ½À´Ï´Ù. °°Àº Ãâó´Â õ½ÄÀÌ ¼ºÀÎ ³²¼ºº¸´Ù ¿©¼º ¼ºÀο¡°Ô ´õ ¸¹ÀÌ º¸ÀÎ´Ù°í ¸»ÇÕ´Ï´Ù.

¶ÇÇÑ ¹Ì±¹Àº È£Èí±â ÁúȯÀÇ ºÎ´ãÀ» ÁÙÀÌ´Â ¾Ð·Â¿¡ ³ëÃâµÇ¾î ÀÖÀ¸¸ç °æÁ¦Àû ¿µÇâÀº ½É°¢ÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, 2021³â 3¿ù ±¹Á¦ COPD Àú³Î¿¡ °ÔÀçµÈ ³í¹®¿¡¼­ ¿¬±¸ÀÚµéÀº COPDÀÇ ¿¬°£ Á÷Á¢ ºñ¿ëÀ» ÃßÁ¤ÇÏ°í ÀÖ½À´Ï´Ù. ¹Ì±¹ÀÇ ¸ÅÃâÀº 180¾ï ´Þ·¯·Î 2030³â±îÁö 220¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

°Ô´Ù°¡ Á¤ºÎ ¹× ºñÁ¤ºÎ Á¶Á÷ÀÇ ³ë·ÂÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Àüü ¼öÀÍÀÌ Áõ°¡ÇÏ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, CDCÀÇ ±¹°¡ õ½Ä °ü¸® ÇÁ·Î±×·¥(NACP)Àº õ½ÄÀ» ¾Î°í Àִ ȯÀÚÀÇ ±³À°¿¡ ÀÚ±ÝÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ³ë·ÂÀº õ½Ä¿¡ ´ëÇÑ ÀǽÄÀ» ³ôÀÏ ¼ö ÀÖ¾î ÆóÈ°·®ÃøÁ¤°Ë»çÀÇ Ã¤¿ëÀÌ Áõ°¡ÇÏ¿© ¿¹Ãø±â°£ µ¿¾È ½ÃÀåÀÇ ¼ºÀåÀÌ È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

°Ô´Ù°¡ ÀÌ Áö¿ª¿¡¼­ÀÇ Á¦Ç° ½ÂÀΰú »ó½Ã Áõ°¡µµ ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÏ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2021³â 4¿ù Vitalograph´Â Â÷¼¼´ë Pneumotrac ÆóÈ°·®°è¸¦ ¹Ì±¹¿¡¼­ Ãâ½ÃÇß½À´Ï´Ù. Pneumotrac ½ºÆÄÀ̷ιÌÅÍ´Â Spirotrac PC ¼ÒÇÁÆ®¿þ¾î¿Í ÅëÇÕµÇ¾î ¼ºÀΰú ¼Ò¾Æ ¸ðµÎ¿¡¼­ È£Èí±â Áø´ÜÀ» À§ÇÑ °­·ÂÇÑ µµ±¸ÀÔ´Ï´Ù.

±×·¯¹Ç·Î È£Èí±â Áúȯ ºÎ´ã Áõ°¡¿Í Á¦Ç° ½ÂÀÎ Áõ°¡¿Í °°Àº ¿äÀÎÀ¸·Î ÀÎÇØ Á¶»ç ´ë»ó ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È ºÏ¹Ì¿¡¼­ ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÆóÈ°·®°è ¾÷°è °³¿ä

ÆóÈ°·®°è ½ÃÀåÀº Àû´çÈ÷ ¼¼ºÐÈ­µÇ¾î ÀÖÀ¸¸ç ¿©·¯ ÁÖ¿ä ±â¾÷À¸·Î ±¸¼ºµÇ¾î ÀÖ½À´Ï´Ù. ½ÃÀå ¼ºÀå¿¡ Å©°Ô °øÇåÇÏ´Â ±â¾÷ÀÇ Á¸Àç°¨µµ Å®´Ï´Ù. Á¦Ç° Çõ½Å°ú ÷´Ü ±â¼ú °³¹ßÀ» À§ÇÑ Áö¼ÓÀûÀÎ R&D È°µ¿ÀÌ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇØ ¿Ô½À´Ï´Ù. ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À¸·Î´Â MGC Diagnostics Corporation, NDD Medical Technologies, KoKo PFT, Koninklijke Philips NV, ICU Medical, Inc. µîÀÌ ÀÖ½À´Ï´Ù.

±âŸ ÇýÅÃ

  • ¿¢¼¿ Çü½Ä ½ÃÀå ¿¹Ãø(ME) ½ÃÆ®
  • 3°³¿ùÀÇ ¾Ö³Î¸®½ºÆ® ¼­Æ÷Æ®

¸ñÂ÷

Á¦1Àå ¼­·Ð

  • Á¶»çÀÇ ÀüÁ¦Á¶°Ç°ú ½ÃÀåÀÇ Á¤ÀÇ
  • Á¶»ç ¹üÀ§

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå ¿ªÇÐ

  • ½ÃÀå °³¿ä
  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¸¸¼º Æó»ö¼º ÆóÁúȯ(COPD)ÀÇ À¯º´·ü Áõ°¡
    • ÆóÈ°·®°è ºÐ¾ßÀÇ ±â¼ú Áøº¸
    • ÀçÅà Çコ Äɾ ´ëÇÑ °ü½É Áõ´ë
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ¸¸¼º Æó»ö¼º ÆóÁúȯ(COPD)¿¡ ´ëÇÑ ÀνÄÀÇ ºÎÁ·
  • Porter's Five Forces ºÐ¼®
    • ½Å±Ô Âü°¡¾÷üÀÇ À§Çù
    • ±¸¸ÅÀÚÀÇ Çù»ó·Â
    • °ø±Þ±â¾÷ÀÇ Çù»ó·Â
    • ´ëü Á¦Ç°ÀÇ À§Çù
    • °æÀï ±â¾÷°£ °æÀï °ü°èÀÇ °Ý·Ä

Á¦5Àå ½ÃÀå ¼¼ºÐÈ­

  • À¯Çüº°
    • ÇÚµåÇïµå
    • Ź»óÇü
  • ±â¼úº°
    • üÀû ÃøÁ¤
    • À¯·® ÃøÁ¤
  • ¿ëµµº°
    • õ½Ä
    • COPD
    • ³¶Æ÷¼º ¼¶À¯Áõ
    • ±âŸ ¿ëµµ
  • ÃÖÁ¾ »ç¿ëÀÚº°
    • º´¿ø ¹× Áø·á¼Ò
    • ÀçÅà ÇコÄɾî
  • Áö¿ª
    • ºÏ¹Ì
      • ¹Ì±¹
      • ij³ª´Ù
      • ¸ß½ÃÄÚ
    • À¯·´
      • µ¶ÀÏ
      • ¿µ±¹
      • ÇÁ¶û½º
      • ÀÌÅ»¸®¾Æ
      • ½ºÆäÀÎ
      • ±âŸ À¯·´
    • ¾Æ½Ã¾ÆÅÂÆò¾ç
      • Áß±¹
      • ÀϺ»
      • Àεµ
      • È£ÁÖ
      • Çѱ¹
      • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
      • GCC
      • ³²¾ÆÇÁ¸®Ä«
      • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¹Ì
      • ºê¶óÁú
      • ¾Æ¸£ÇîƼ³ª
      • ±âŸ ³²¹Ì

Á¦6Àå °æÀï ±¸µµ

  • ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • Baxter International(Hill-Rom Services, Inc)
    • Jones Medical Instrument Company
    • MGC Diagnostics Corporation
    • Midmark Corporation
    • NDD Medical Technologies
    • KoKo PFT
    • OHD(SCHAUENBURG International Group)
    • Koninklijke Philips NV
    • ICU Medical, Inc.
    • Teleflex Incorporated
    • Vitalograph
    • Vyaire Medical Inc.

Á¦7Àå ½ÃÀå ±âȸ¿Í ¹Ì·¡ µ¿Çâ

JHS 24.03.20

The Spirometers Market size is estimated at USD 602.70 million in 2024, and is expected to reach USD 803.89 million by 2029, growing at a CAGR of 5.93% during the forecast period (2024-2029).

Spirometers - Market

COVID-19 impacted the growth of the spirometer market owing to the decline in the diagnosis and treatment of patients suffering from respiratory diseases. For instance, according to the research study published in Elsevier Public Health Emergency, September 2021, it has been observed that the use of spirometry is restricted to immunocompromised patients for urgent treatment only, such as bone marrow transplants, lung transplants, and pre-chemotherapy treatments. Also, according to the research study published in PLOS One in February 2021, it has been observed that the risk for all-cause mortality is approximately two times higher in patients with COPD than in those without COPD, and a steep decline in visits to hospitals and clinics due to the lockdown measures imposed by the government has severely impacted the market growth during a pandemic. However, resumed diagnosis and treatment services for respiratory diseases and increased patient visits have increased market growth, are expected to regain their potential over the years, and may record healthy growth during the forecast period.

Factors such as the rise in the prevalence of chronic obstructive pulmonary disease (COPD), technological advancements in the field of spirometers, and a growing preference for home healthcare are boosting market growth.

The rising burden of COPD among the population raises the need for early detection of the COPD condition, which is expected to fuel the demand for spirometry tests. This is anticipated to augment market growth over the forecast period. For instance, as per an article published in the European Respiratory Journal, in November 2021, about 49,453,852 Europeans are expected to suffer from COPD by 2050, as compared to 36,580,965 in 2020. In addition, as per the same source, the Netherlands is expected to have the highest prevalence of COPD (14.6%) in Europe by 2050.

Additionally, according to the study published in PLOS ONE in January 2021, in France, there are currently 2.6 million people who have chronic obstructive pulmonary disease (COPD), and by 2025, that number is expected to rise to 2.8 million. Also, as per the 2022 statistics published by the NHS, about 1.17 million people in England were diagnosed with chronic obstructive pulmonary disorder (COPD) in 2020-2021, accounting for 1.9% of the total population. Thus, the expected increase in the number of people suffering from COPD is expected to increase the demand for technologically advanced spirometers, hence propelling market growth.

Furthermore, technological advances and the increasing portability and ease of operation of devices are anticipated to drive segment growth. For instance, in March 2021, Vyaire Medical launched the AioCare (HealthUp SA, Poland) mobile spirometry system in more than 15 countries, including Australia and other countries. This clinically proven technology expands upon Vyaire's deep respiratory diagnostics expertise and allows physicians to promptly diagnose pulmonary diseases including asthma and COPD as accurately as hospital-grade spirometers.

Moreover, the preference for home healthcare has increased among patients, which has increased the development of tele-spirometers or virtual spirometry tests, which is also contributing to the market's growth. For instance, in June 2021, eResearch Technology (ERT) launched ERT iSpiro Virtual Visits, which enables real-time coaching during at-home pulmonary function tests (PFT). iSpiro Virtual Visits makes it possible to gather high-quality spirometry data at home, keeping respiratory clinical studies on schedule, even when a patient is unable to visit a clinic.

Therefore, owing to the aforementioned factors, the studied market is expected to grow over the forecast period. But not enough people know about chronic obstructive pulmonary disease (COPD), which is likely to slow the growth of the spirometer market over the next few years.

Spirometers Market Trends

Hand-Held is Expected to Witness Significant Growth in the Spirometers Market

The hand-held spirometers segment is expected to witness significant growth in the spirometers market over the forecast period owing to factors such as the increasing number of COPD and asthma cases, the growing number of smokers across the globe, and increasing product launches.

Hand-held spirometers are small, lightweight, and easily portable, thereby becoming more ubiquitous in the industry. The advantages of hand-held spirometers over conventional spirometers, such as being easy to use and being able to be used outside the hospital setting too, are expected to augment segment growth.

According to an article published in Primary Care Respiratory Medicine in April 2022, the accuracy of three portable spirometers, the PIKO-6, COPD-6, and PEF, was determined. It has been observed that the accuracy of PIKO-6 was higher (0.95) than that of COPD-6 (0.91) and PEF (0.82). In addition, as per the same source, portable spirometers, such as the PIKO-6 and COPD-6, can provide a variety of respiratory function indicators that aid in the diagnosis of COPD patients, as well as in determining the severity of the condition and assisting in the selection of an effective treatment strategy. Thus, portable spirometers are ideal for primary care use and offer a practical method for the early detection of COPD due to their high accuracy, user-friendliness, patient-friendliness, affordability, and portability. This is expected to increase their adoption among patients, hence propelling the segment's growth.

Furthermore, the rising company activities and increasing product launches are also expected to increase the availability of hand-held spirometer devices, which in turn is anticipated to fuel the segment's growth. For instance, in November 2021, Cipla launched a pneumotach-based portable, wireless spirometer in India. With this launch, the company intends to revolutionize obstructive airway disease (OAD) diagnosis, in line with its ambition to strengthen its position as the lung leader in India.

Therefore, owing to the aforementioned factors, such as the growing number of smokers, the increasing burden of COPD, and increasing product launches, the studied segment is expected to grow over the forecast period.

North America is Expected to Have the Significant Market Share Over the Forecast Period

North America is expected to witness healthy growth in the spirometer market over the forecast period. The factors contributing to market growth are the rising prevalence and incidences of respiratory diseases, the presence of a well-established healthcare infrastructure along with high healthcare spending, and the growing adoption of home-health devices among consumers.

The rising burden of respiratory diseases such as asthma, COPD, and others is expected to increase the demand for spirometers, thereby boosting market growth. For instance, according to the Asthma and Allergy Foundation of America (AAFA), in April 2022, roughly 1 in 13 Americans had asthma, which is about 25 million people. According to the same source, about 5.1 million American children have asthma under the age of 18. The same source stated that asthma is more common in female adults than in male adults.

Furthermore, the United States is under pressure to reduce the burden of respiratory disease, and the economic impact is significant.For instance, in an article published in the International Journal of COPD in March 2021, the researchers estimated that the annual direct costs of COPD in the United States are USD 18 billion and are expected to reach USD 22 billion by 2030.

Furthermore, the rise in the number of initiatives undertaken by government and non-government organizations is increasing overall revenue. For instance, the CDC's National Asthma Control Program (NACP) provides funds for educating asthma-affected patients. Such initiatives are likely to increase awareness about asthma, which will increase the adoption of spirometry tests, which in turn is anticipated to augment market growth over the forecast period.

Moreover, the increasing product approvals and launches in the region are also contributing to market growth. For instance, in April 2021, Vitalograph launched a next-generation Pneumotrac spirometer in the United States. The Pneumotrac spirometer is integrated with Spirotrac PC software and is a powerful tool for respiratory diagnosis in both adults and pediatrics.

Therefore, owing to factors such as the high burden of respiratory diseases and increasing product approvals, the studied market is expected to grow in the North America region over the forecast period.

Spirometers Industry Overview

The spirometer market is moderately fragmented and consists of several major players. There has been a significant presence of companies that are significantly contributing to the market's growth. Product innovation and ongoing R&D activities to develop advanced technologies have helped boost the growth of the market. Some of the major players in the market are MGC Diagnostics Corporation, NDD Medical Technologies, KoKo PFT, Koninklijke Philips N.V., and ICU Medical, Inc., among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rise in Prevalence of Chronic Obstructive Pulmonary Disease (COPD)
    • 4.2.2 Technological Advancements in the Field Of Spirometers
    • 4.2.3 Growing Preference for Home Healthcare
  • 4.3 Market Restraints
    • 4.3.1 Lack of Awareness regarding Chronic Obstructive Pulmonary Disease (COPD)
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Type
    • 5.1.1 Hand-Held
    • 5.1.2 Table-Top
  • 5.2 By Technology
    • 5.2.1 Volume Measurement
    • 5.2.2 Flow Measurement
  • 5.3 By Application
    • 5.3.1 Asthma
    • 5.3.2 COPD
    • 5.3.3 Cystic Fibrosis
    • 5.3.4 Other Applications
  • 5.4 By End-User
    • 5.4.1 Hospitals and Clinics
    • 5.4.2 Home Healthcare
  • 5.5 Geography
    • 5.5.1 North America
      • 5.5.1.1 United States
      • 5.5.1.2 Canada
      • 5.5.1.3 Mexico
    • 5.5.2 Europe
      • 5.5.2.1 Germany
      • 5.5.2.2 United Kingdom
      • 5.5.2.3 France
      • 5.5.2.4 Italy
      • 5.5.2.5 Spain
      • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
      • 5.5.3.1 China
      • 5.5.3.2 Japan
      • 5.5.3.3 India
      • 5.5.3.4 Australia
      • 5.5.3.5 South Korea
      • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East and Africa
      • 5.5.4.1 GCC
      • 5.5.4.2 South Africa
      • 5.5.4.3 Rest of Middle East and Africa
    • 5.5.5 South America
      • 5.5.5.1 Brazil
      • 5.5.5.2 Argentina
      • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Baxter International (Hill-Rom Services, Inc)
    • 6.1.2 Jones Medical Instrument Company
    • 6.1.3 MGC Diagnostics Corporation
    • 6.1.4 Midmark Corporation
    • 6.1.5 NDD Medical Technologies
    • 6.1.6 KoKo PFT
    • 6.1.7 OHD (SCHAUENBURG International Group)
    • 6.1.8 Koninklijke Philips N.V.
    • 6.1.9 ICU Medical, Inc.
    • 6.1.10 Teleflex Incorporated
    • 6.1.11 Vitalograph
    • 6.1.12 Vyaire Medical Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦